<DOC>
	<DOCNO>NCT02061761</DOCNO>
	<brief_summary>The purpose study characterize safety , tolerability maximum tolerate dose BMS-986016 administer alone combination Nivolumab subject relapse hematologic malignancy .</brief_summary>
	<brief_title>Safety Study Anti-LAG-3 Relapsed Refractory Hematologic Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Hematologic Neoplasms</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com For dose escalation monotherapy : CLL , HL , NHL , MM For dose expansion monotherapy : CLL , HL , NHL For dose escalation dose expansion combination BMS936558 : HL DLBCL Progressed , intolerant , least one standard treatment regimen Not eligible decline transplantation standard therapy know life prolong life save Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 At least 1 lesion measurable disease baseline Availability exist tumor biopsy sample ( consent allow pretreatment tumor biopsy sample available ) Known suspected central nervous system ( CNS ) metastases CNS site active disease ( control CNS metastasis allow ) Autoimmune disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>